Page 14 - மருத்துவ புற்றுநோயியல் நிபுணர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article PARIS, May 19, 2021 /PRNewswire/  Phase 1 data from the AMEERA-1 study evaluating amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. In a pooled analysis, amcenestrant in combination with palbociclib showed encouraging antitumor activity in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). These early clinical data show that the combination of amcenestrant with palbociclib achieved encouraging antitumor activity, said Sarat Chandarlapaty, M.D., Ph.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center. The analysis also demonstrated no clinically significant cardiac or ocular findings and an overall safety profile in line with what we saw in the monotherapy setting. It s notable to see this kind of activity in patients with ER+ me

United statesFrance generalEva schaefer jansenArnaud delepineSuzanne grecoFelix lauscherJohn reedSarat chandarlapatyFara berkowitzSally bainGlobal head of researchAmerican society of clinical oncologyData safety monitoring committeeMemorial sloan kettering cancer centerClinical oncologyMedical oncologist